EUVIMEDEUVIMED entdecken
Crossref

Multifactorial 1, 3, 4‐Oxadiazole Derivatives as Cholinesterase and Glycogen Synthase Kinase‐3 β Inhibitors for Targeting Alzheimer's Disease: QSAR‐Based Virtual Screening, MD Docking, Free Energy Analysis, ADMET, and DFT Studies

Nikita Chhabra, Balaji Wamanrao Matore, Anjali Murmu, Jagadish Singh, Partha Pratim Roy

Journal of Chemometrics · 2026-02 · 40 (2)

DOI: 10.1002/cem.70107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Chemometrics, online erschienen am 09.02.2026. Verfasst von Nikita Chhabra und 4 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 78 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) involves multiple pathogenic pathways, yet current therapeutic strategies remain largely symptomatic and focused on single molecular targets, underscoring a critical existing gap, emphasizing the need for rational multitarget drug design. Addressing this limitation, the present study employed an integrated in silico framework to identify multitarget 1,3,4‐oxadiazole derivatives against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and glycogen synthase kinase‐3 β (GSK3β). A dataset of 273 reported compounds was used to develop robust QSAR models via Genetic Algorithm‐Multiple Linear Regression (GA‐MLR), exhibiting strong internal ( R 2 = 0.638–0.758, Q 2 LOO = 0.609–0.736) and satisfactory external predictivity ( Q 2 F1 − Q 2 F2 = 0.566–0.800). Subsequent virtual screening of 3404 1,3,4‐oxadiazoles from BindingDB identified 72 promising hits (IC₅₀ ≤ 300 nM), which underwent molecular dynamics (MD) docking. MD‐based CDOCKER analysis highlighted compound 2851 with superior binding energies and stable key interactions compared to donepezil, supported by binding free energy (Δ G ) calculations. ADMET evaluation indicated favorable pharmacokinetic and toxicity profiles, while density functional theory (DFT) analysis revealed enhanced reactivity and lower band gaps. This integrated computational workflow identified compound 2851 as a promising MT therapeutic agent for AD.

Zitieren

APA

Chhabra, N., Matore, B. W., Murmu, A., Singh, J., & Roy, P. P. (2026). Multifactorial 1, 3, 4‐Oxadiazole Derivatives as Cholinesterase and Glycogen Synthase Kinase‐3 β Inhibitors for Targeting Alzheimer's Disease: QSAR‐Based Virtual Screening, MD Docking, Free Energy Analysis, ADMET, and DFT Studies. Journal of Chemometrics, 40(2). https://doi.org/10.1002/cem.70107

Vancouver

Chhabra N, Matore BW, Murmu A, Singh J, Roy PP. Multifactorial 1, 3, 4‐Oxadiazole Derivatives as Cholinesterase and Glycogen Synthase Kinase‐3 β Inhibitors for Targeting Alzheimer's Disease: QSAR‐Based Virtual Screening, MD Docking, Free Energy Analysis, ADMET, and DFT Studies. Journal of Chemometrics. 2026;40(2). doi:10.1002/cem.70107

BibTeX
@article{Chhabra2026,
  author = {Chhabra, Nikita and Matore, Balaji Wamanrao and Murmu, Anjali and Singh, Jagadish and Roy, Partha Pratim},
  title = {Multifactorial 1, 3, 4‐Oxadiazole Derivatives as Cholinesterase and Glycogen Synthase Kinase‐3 β Inhibitors for Targeting Alzheimer's Disease: QSAR‐Based Virtual Screening, MD Docking, Free Energy Analysis, ADMET, and DFT Studies},
  journal = {Journal of Chemometrics},
  year = {2026},
  volume = {40},
  number = {2},
  doi = {10.1002/cem.70107}
}
Kostenlos starten →